The article by Lemos et al 1 describing coronary restenosis after implantation of sirolimus-eluting stents is of great interest. With the increasing demand for drug-eluting stents (DES) and the recent formation of guidelines for their use, confirmation of their continued efficacy in reducing restenosis is important. Therefore, registry data from a large patient population such as the Thoraxcenter (Rotterdam, the Netherlands)-probably the largest DES patient population in the world-is greatly welcomed.
